Travere Net Working Capital from 2010 to 2025

TVTX Stock  USD 21.13  0.48  2.32%   
Travere Therapeutics Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2025. During the period from 2010 to 2025, Travere Therapeutics Net Working Capital regression line of annual values had r-squared of  0.39 and arithmetic mean of  299,885,343. View All Fundamentals
 
Net Working Capital  
First Reported
2020-03-31
Previous Quarter
134.7 M
Current Value
216 M
Quarterly Volatility
105.7 M
 
Covid
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 277.3 M, Other Operating Expenses of 581.5 M or Total Operating Expenses of 584.9 M, as well as many indicators such as Price To Sales Ratio of 6.84, Dividend Yield of 0.0 or PTB Ratio of 22.1. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Travere Therapeutics over the last few years. It is Travere Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Travere Net Working Capital Regression Statistics

Arithmetic Mean299,885,343
Geometric Mean290,592,132
Coefficient Of Variation26.93
Mean Deviation70,238,136
Median240,139,000
Standard Deviation80,749,868
Sample Variance6520.5T
Range242.8M
R-Value0.62
Mean Square Error4257.3T
R-Squared0.39
Significance0.01
Slope10,600,489
Total Sum of Squares97808.1T

Travere Net Working Capital History

2025376.8 M
2024216 M
2023438.9 M
2022344.3 M
2021458.7 M
2020317.7 M
2019333.6 M

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital216 M376.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.